Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Open Access
- 14 November 2011
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (22), 6985-6991
- https://doi.org/10.1158/1078-0432.ccr-11-1331
Abstract
Indoleamine 2,3-dioxygenase (IDO) is a tryptophan-catabolizing enzyme with immune-regulating activities in many contexts, such as fetal protection, allograft protection, and cancer progression. Clinical trials are currently evaluating IDO inhibition with 1-methyltryptophan in cancer immunotherapy. However, the exact role of tryptophan catabolism by IDO in human cancers remains poorly understood. Here, we review several studies that correlate IDO expression in human cancer samples and tumor-draining lymph nodes, with relevant clinical or immunologic parameters. IDO expression in various histologic cancer types seems to decrease tumor infiltration of immune cells and to increase the proportion of regulatory T lymphocytes in the infiltrate. The impact of IDO on different immune cell infiltration leads to the conclusion that IDO negatively regulates the recruitment of antitumor immune cells. In addition, increased IDO expression correlates with diverse tumor progression parameters and shorter patient survival. In summary, in the vast majority of the reported studies, IDO expression is correlated with a less favorable prognosis. As we may see results from the first clinical trials with 1-methyltryptophan in years to come, this review brings together IDO studies from human studies and aims to help appreciate outcomes from current and future trials. Consequently, IDO inhibition seems a promising approach for cancer immunotherapy. Clin Cancer Res; 17(22); 6985–91. ©2011 AACR.Keywords
This publication has 48 references indexed in Scilit:
- Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulatorsBlood, 2011
- Reprogrammed Foxp3+ Regulatory T Cells Provide Essential Help to Support Cross-presentation and CD8+ T Cell Priming in Naive MiceImmunity, 2010
- B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenaseProceedings of the National Academy of Sciences of the United States of America, 2010
- Expression of indoleamine 2,3-dioxygenase in nasopharyngeal carcinoma impairs the cytolytic function of peripheral blood lymphocytesBMC Cancer, 2009
- The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancerJournal of Translational Medicine, 2009
- Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancerBMC Cancer, 2009
- Genotyping and Expression Analysis of IDO2 in Human Pancreatic Cancer: A Novel, Active TargetJournal of the American College of Surgeons, 2009
- Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammationProceedings of the National Academy of Sciences of the United States of America, 2008
- Mechanisms of local immunosuppression in cutaneous melanomaBritish Journal of Cancer, 2007
- Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancerBritish Journal of Cancer, 2006